Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Italy’s Alfasigma SpA in a ...

Opens in a new tab or window Members of an international team of experts in atopic dermatitis (AD) have recommended oral JAK inhibitors for patients with moderate-to-severe AD. That's just one ...

JAK inhibitors, such as ruxolitinib and upadacitinib ... FDA-approved: Refers to drugs that have been evaluated and authorized by the U.S. Food and Drug Administration for safety and efficacy ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Phosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains their synergy with Gemcitabine in ...

Covalent inhibitors are a class of drugs that form a permanent bond with their target proteins, leading to prolonged inhibition of their activity. This approach has gained significant traction in ...

Lilly and Incyte's already-marketed JAK inhibitor Olumiant (baricitinib) is currently in the lead among drugs for alopecia areata, with a filing due in the second half of this year after two ...

Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has ...

The celebrity dermatologist talks about finding her moment of clarity in finding relief for her eczema symptoms and how she ...

Now, more than 25 years into her journey with vitiligo, Lisa reflects on the impact of vitiligo and how she’s managed the ...